<DOC>
	<DOCNO>NCT01018784</DOCNO>
	<brief_summary>MORAb-009 intravenously administer patient solid tumor week 4 week 1 cycle order investigate dose-limiting toxicity estimate maximum tolerate dose .</brief_summary>
	<brief_title>A Study MORAb-009 Patients With Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion ; 1 . Japanese male female patient age 20 less 80 year obtain informed consent 2 . Patient histologically cytologically diagnose solid tumor 3 . Patient mesothelinpositive confirm immunohistochemistry ( IHC ) ( except pancreatic cancer mesothelioma mesothelinpositive frequently report ) 4 . Patient solid tumor non responder resistant standard therapy appropriate treatment 5 . Performance Status ( PS ) 0 1 Eastern Cooperative Oncology Group ECOG criterion Exclusion criterion 1 . Brain metastasis present clinical symptom require medical treatment 2 . Serious systemic infection require medical treatment 3 . History hypersensitivity protein formulation include monoclonal antibody 4 . With active multiple carcinoma ( except carcinoma situ intramucosal carcinoma ) 5 . With celomic fluid ( pleural effusion ascites ) uncontrolled drainage , large volume celomic fluid</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Mesothelin-positive</keyword>
</DOC>